Journal of Oncology / 2020 / Article / Tab 1

Review Article

EGFR Polymorphism and Survival of NSCLC Patients Treated with TKIs: A Systematic Review and Meta-Analysis

Table 1

General characteristics of the included studies.

Author, yearCountryStudy periodNo. of patientsMedian age, years (range)Gender (males, %)Ethnicity (%)Smokers (%)Clinical stage (%)Median follow-up in monthsTKI (dose)Additional therapy

Han et al., 2007 [55]KoreaJan 2002–Dec 20048661 (30–87)57.0NR55.8IIIB (5.8); IV (94.2)16.9Gefitinib (250 mg/d)NR

Ichihara et al., 2007 [26]JapanNov 2000–May 20069866 (NR)63.0NR62.0NRb11.4cGefitinib (250 mg/d)88.0% of patients previously treated with chemotherapy

Liu et al., 2008 [56]USA and CanadaDec 2000–Feb 20039261 (36–87)41.0Caucasian (95); Asian (3); African American (2)79.0IIIB (7.0); IV (93.0)28.5 (PFS); 29.9 (OS)Gefitinib (NR)85.0% of patients were previously, and 95% concurrently treated with chemotherapy

Giovannetti et al., 2010 [57]ItalyNR9664 (NR)57.3NR68.8IIIB (9.4); IV (90.6)NRGefitinib (250 mg/d)84.5% of patients were previously treated with chemotherapyd

Tiseo et al., 2010 [58]ItalyNR9167 (40–85)61.5Caucasian (100)78.0III (11.0); IV (89.0)NRGefitinib (250 mg/d)All patients were previously treated with chemotherapy

Nie et al., 2011 [60]ChinaJun 2002–Sep 2006–Jul 2010a115e57 (NR)56.5NRNRIV (83.5)54.0Gefitinib (250 mg/d) or erlotinib (150 mg/d)All patients were previously treated with chemotherapy

Jung et al., 2012 [25]KoreaJan 2007–Dec 201071f59 (34–85)62.0Asian (100)57.7NR12.7Gefitinib (250 mg/d) or erlotinib (150 mg/d)All patients were previously treated with chemotherapy

Zhang et al., 2013 [31]ChinaJan 2008–Dec 201012855 (32–80)48.4NR32.0IIIB (25.0); IV (75.0)16.6Gefitinib (250 mg/d)All patients were previously treated with one or two other therapy options

Winther-Larsen et al., 2014 [59]DenmarkJan 2007–Oct 201162g65 (33–88)40.0Caucasian (100)16.0IV (100)52.2Erlotinib (150 mg/d, dose reduced in case of side effects grade 2 or higher)NR

Winther-Larsen et al., 2015 [32]DenmarkJan 2007–Apr 201433164 (34–89)46.0Caucasian (100)26.0IV (100)62.7Erlotinib (150 mg/d, dose reduced in case of side effects grade 2 or higher)84.0% and 10% of patients were previously treated with platinum-based and pemetrexed and/or docetacel-based chemotherapy, respectively

Kim et al., 2017 [61]Italy and CanadaNR76062 (27–81)66.3East Asian (3.2); other (96.8)79.3IIIB (10.9); IV (89.1)36.0Erlotinib (150 mg/d)50% of patients were treated with erlotinib, followed by cisplatin and gemcitabine at progression; other 50% were treated with cisplatin and gemcitabine, followed by erlotinib at progression

NR: not reported. aLast follow-up. bBased on the Eastern Cooperative Oncology Group performance status, there were 61.0% with grade 0/1 and 39.0% with grade 2/3/4. cFor survivors. dAdditional 127 chemotherapy-treated/gefitinib-nontreated NSCLC patients were used as a comparison. e70 on gefitinib and 45 on erlotinib. f37 on gefitinib and 34 on erlotinib. gAll were EGFR mutation positive.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.